Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ridinilazole (SMT19969) is a novel narrow-spectrum nonabsorbable antibiotic. Ridinilazole showed potent inhibition of C. difficile (MIC90=0.125 mg/L) and was markedly more active than either metronidazole (MIC90 = 8 mg/L) or vancomycin (MIC90 = 2 mg/L).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 97.00 | |
2 mg | In stock | $ 132.00 | |
5 mg | In stock | $ 197.00 | |
10 mg | In stock | $ 337.00 | |
25 mg | In stock | $ 572.00 | |
50 mg | In stock | $ 818.00 | |
100 mg | In stock | $ 1,130.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 168.00 |
Description | Ridinilazole (SMT19969) is a novel narrow-spectrum nonabsorbable antibiotic. Ridinilazole showed potent inhibition of C. difficile (MIC90=0.125 mg/L) and was markedly more active than either metronidazole (MIC90 = 8 mg/L) or vancomycin (MIC90 = 2 mg/L). |
Targets&IC50 | C. difficile:8 µg/mL (MIC90) |
In vivo | ridinilazole , a novel antibacterial currently under development for the treatment of CDI.?Owing to its highly targeted spectrum of activity and ability to spare the normal gut microbiota, ridinilazole provides significant advantages over metronidazole and vancomycin, the mainstay antibiotics for CDI.?Ridinilazole is bactericidal against C. difficile and exhibits a prolonged post-antibiotic effect.?Furthermore, treatment with ridinilazole results in decreased toxin production. |
Synonyms | SMT19969 |
Molecular Weight | 388.42 |
Formula | C24H16N6 |
CAS No. | 308362-25-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (141.6 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ridinilazole 308362-25-6 Microbiology/Virology Antibacterial inhibit Bacterial SMT-19969 SMT 19969 SMT19969 Inhibitor inhibitor